Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 19, 2024The Medical Journal of AustraliaOpen Access

Contextualising the benefits and risks of anti‐amyloid therapy for patients with Alzheimer disease and their care team

View Full Paper
Ask AI
Bookmark
Share

Authors

OBOneil G. BhalalaJTJane ThompsonRWRosie Watson

Discussion

Loading...

Member takes

Overview

Perspective article demonstrates modest cognitive slowing alongside notable safety risks in early Alzheimer disease, highlighting the need for individualized clinical decisions.

Key Points

  • Amyloid beta clearance by novel monoclonal antibodies yields robust plaque removal, yet observed clinical cognitive benefits remain relatively modest in early Alzheimer disease.
  • Cognitive decline slowed by approximately 0.5 points on the clinical dementia rating scale over 18 months, preserving functional independence in early Alzheimer disease.
  • Assessment of phase 3 trials evaluated lecanemab and donanemab across multiple cognitive metrics, incorporating positron emission tomography to verify amyloid status.
  • Highlights the need to balance modest therapeutic gains against surveillance burdens and safety hazards when administering monoclonal antibodies for Alzheimer disease.

Cite This Study

Bhalala et al. (2024) studied this question.

synapsesocial.com/papers/68e6417fb6db6435875d2f60https://doi.org/10.5694/mja2.52359
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Lecanemab: Appropriate Use Recommendations2023 · 915 citations
  2. 2Lecanemab in Early Alzheimer’s Disease2022 · 5,719 citations
  3. 3Expectations and clinical meaningfulness of randomized controlled trials2023 · 96 citations
  4. 4Donanemab in Early Symptomatic Alzheimer Disease2023 · 2,897 citations
  5. 5The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease2022 · 286 citations